Clinical Trial

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 7, 2024 (before its estimated February 9, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based chemotherapy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-16
Trial Details
NCT Number NCT06259721
Lead Sponsor Jiangxi Provincial Cancer Hospital
Conditions Nasopharyngeal Carcinoma
Enrollment 22 participants
Start Date 2024-02-10
Primary Completion 2026-02-09 (estimated)
Study Completion 2026-08-09 (estimated)
Updated on ClinicalTrials.gov 2024-03-07